Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome

    Research output: Contribution to journalArticlepeer-review

    30 Citations (Scopus)


    Recent studies have shown that more than 80% of bone marrow samples from patients with myelodysplastic syndrome (MDS) harbour somatic mutations and/or genomic aberrations, which are of diagnostic and prognostic importance. We have investigated the potential use of peripheral blood and serum to identify and monitor bone marrow derived genetic markers using high-resolution single nucleotide polymorphism array karyotyping (SNP-A) and parallel sequencing of 22 genes frequently mutated in MDS. This pilot study, showed a 100% SNP-A karyotype concordance and 97% mutation concordance between the bone marrow and peripheral blood. In contrast mutation analysis by Sanger sequencing of peripheral blood and serum derived DNA showed only 65% and 42% concordance, respectively to bone marrow. Our results show the potential utility of peripheral blood as a surrogate for bone marrow for MDS patients avoiding the need for repeated bone marrow aspirates particularly in elderly patients and those with fibrotic or hypocellular marrows.
    Original languageEnglish
    Pages (from-to)567-570
    Number of pages4
    Issue number4
    Early online date25 Jul 2013
    Publication statusPublished - 2013
    Event54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - Atlanta, Gabon
    Duration: 8 Dec 201211 Dec 2012


    • MDS
    • FISH


    Dive into the research topics of 'Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome'. Together they form a unique fingerprint.

    Cite this